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Prostacyclin reverses platelet stress 
fibre formation causing platelet 
aggregate instability
M. Z. Yusuf1, Z. Raslan1, L. Atkinson1, A. Aburima1, S. G. Thomas  2,3, K. M. Naseem1 & S. D. J. 
Calaminus1
Prostacyclin (PGI2) modulates platelet activation to regulate haemostasis. Evidence has emerged 
to suggest that thrombi are dynamic structures with distinct areas of differing platelet activation. 
It was hypothesised that PGI2 could reverse platelet spreading by actin cytoskeletal modulation, 
leading to reduced capability of platelet aggregates to withstand a high shear environment. Our data 
demonstrates that post-flow of PGI2 over activated and spread platelets on fibrinogen, identified a 
significant reduction in platelet surface area under high shear. Exploration of the molecular mechanisms 
underpinning this effect revealed that PGI2 reversed stress fibre formation in adherent platelets, 
reduced platelet spreading, whilst simultaneously promoting actin nodule formation. The effects 
of PGI2 on stress fibres were mimicked by the adenylyl cyclase activator forskolin and prevented by 
inhibitors of protein kinase A (PKA). Stress fibre formation is a RhoA dependent process and we found 
that treatment of adherent platelets with PGI2 caused inhibitory phosphorylation of RhoA, reduced 
RhoA GTP-loading and reversal of myosin light chain phosphorylation. Phospho-RhoA was localised 
in actin nodules with PKA type II and a number of other phosphorylated PKA substrates. This study 
demonstrates that PGI2 can reverse key platelet functions after their initial activation and identifies a 
novel mechanism for controlling thrombosis.
In healthy blood vessels platelets are exposed to endothelial derived nitric oxide (NO) and prostacyclin (PGI2) 
which act to inhibit platelet activation1. However, upon vascular damage platelets overcome this inhibition allow-
ing the formation of a thrombus. Within the thrombus, the activation status of the platelet is determined by 
the relative activatory and inhibitory signalling in the microenvironment of the vascular lesion and its location 
within the thrombus. Here, fully activated platelets are found within a core region, while those at the periphery 
are only weakly activated2. However, the diffusion of platelet agonists within the thrombus is not uniform3, and 
furthermore there is little known on the diffusion of the endogenous platelets inhibitors, NO and PGI2, within the 
thrombus. Furthermore as endothelial release of PGI2 is induced by the activity of thrombin4, this brings forward 
the idea that this induction of PGI2 by thrombin is not only limited to the inhibition of non-stimulated platelets, 
but also to reverse the activation of activated platelets within the thrombus in order to effectively control the 
extent of the thrombus formation induced by the injury.
In order for platelets to be able to form thrombi effectively within the high shear environment of the vas-
culature, platelet adhesion at sites of vascular damage leads to significant remodeling of the actin cytoskeleton. 
The reorganization of the actin cytoskeleton is a complex process requiring co-ordinated modulation of actin 
polymerization, in order to drive the sequential formation of filopodia, actin nodules, lamellipodia and stress 
fibres (reviewed in ref. 5). Individual members of the RhoGTPase family have been implicated in this progessive 
remodeling of the cell architechture. Cdc42 drives filopodia formation6, Rac activation of WASP and the Arp2/3 
complex generates lamellipodia7, and RhoA activity drives stress fibre formation8. At present it is unclear which 
RhoGTPase is responsible for actin nodule formation, although Rac has been identified to be present within the 
nodule9. This reorganization is dynamic, requiring constant signaling in order to prevent lamellipodial collapse10. 
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Defective cytoskeleton remodelling leads to platelet spreading defects, reduction in thrombus size and an increase 
in thrombus instability8, 11–13.
Understanding the role of PGI2 is therefore critical to understand platelet function. PGI2 causes platelet inhi-
bition via binding of PGI2 to the IP receptor, leading to the activation of adenylyl cyclase, and the synthesis of 
cyclic adenosine 3′, 5′ monophosphate (cAMP). Elevated cAMP activates PKA, the primary effector of cAMP 
signalling in platelets, leading to the inhibition of platelet functions in vitro and diminished platelet accrual at sites 
of vascular injury in vivo1. Once activated PKA isoforms blunt multiple aspects of platelet function including Ca2+ 
mobilisation, integrin activation, secretion, although knowledge of how these specific platelet functions are tar-
geted by cAMP signalling remains unclear14–16. Proteomic studies have demonstrated that cAMP/PKA signalling 
targets a cluster of potential proteins associated with cytoskeletal reorganisation suggesting that the cytoskeleton 
is a major target in order to effectively mediate platelet regulation17. In this context, we have recently described 
a mechanism by which cAMP signalling prevented platelet shape change through inhibition of RhoA signalling 
and phosphorylation of myosin light chains (MLC)18. However, the mechanisms by which cyclic nucleotide sig-
naling can return platelets to the resting state after activation, thereby preventing permanent attachment to the 
thrombus or at points distant to the injury, are unknown.
In the present study we examined the role of cAMP in modulating the function of activated platelets. We 
found that cAMP signaling can reverse stress fibre formation, significantly reduce the surface area coverage of the 
platelet, and induce actin nodule formation in a cAMP and PKA dependent manner. This reversal of stress fibre 
formation, and surface area coverage was associated with inhibitory phosphorylation and inactivation of both 
RhoA and the localisation of pRhoA to actin nodules. Furthermore these changes in the actin cytoskeleton were 
associated with a reduction in surface area coverage in platelets flowed over fibrinogen in high shear environment. 
This data identified that PGI2 can reverse platelet activation leading to alteration of the platelets function in a high 
shear environment.
Results
Effect of PGI2 on Platelet aggregate formation on fibrinogen. Previously we have shown that blood 
preincubated with PGI2 (100 nM) can inhibit thrombus formation on fibrinogen19. However the effects of PGI2 on 
activated platelets has not been shown. Therefore, whole blood was flowed over fibrinogen (300 ug/ml) at arterial 
rates of shear (1000 s−1) resulting in the formation of small thrombi and a surface area coverage of 38.2 ± 6.8% 
(Fig. 1 and Supplementary Video. 1). Perfusion of these thrombi with PGI2 (100 nM) led to a significant reduction 
in surface area coverage to 24.4 ± 2.9% (p < 0.05). In contrast, perfusion of the thrombi with buffer alone had no 
significant effect on surface area coverage (Fig. 1a,b and Supplementary Videos 2 and 3). Further analysis of the 
platelets identified that there had been a noticable reduction in surface area in the spread platelets, indicating that 
PGI2 may reverse platelet spreading on fibrinogen.
PGI2 reverses stress fibre formation in spread platelets on fibrinogen. Analysis of platelet spread-
ing in the absence of PGI2 demonstrated within 5 minutes of adhesion, the majority of platelets had formed 
actin nodules, but by 25 minutes that these actin nodules had been replaced by platelets containing stress fibres 
(Supplementary Figure S1). These stress fibres were maintained for up to 45 minutes post adhesion (longest time 
tested) which is consistent with previously published data9. The actin cytoskeleton has been implicated in throm-
bus stability and is known to be modulated by PKA signaling in multiple cell types20–22. Therefore, in the next 
series of experiments PGI2 (10 nM) was added to the spread platelets after 25 minutes, and spreading evaluated 
for a further 60 minutes (Fig. 2a). In the absence of PGI2 the number of platelets with stress fibres did not alter 
appreciably over this timecourse. In contrast the presence of PGI2 caused a rapid loss of actin stress fibres in 
spread platelets. This effect was maximal at 10 minutes post PGI2 treatment before returning to control levels 
after 60 minutes (Fig. 2b,c). Interestingly the loss of stress fibres was associated with the reciprocal appearance 
of circular dot like F-actin rich structures, which was again maximal at 10 minutes before returning to control 
values by 60 minutes (Fig. 2b,d). The F-actin circular structures induced by PGI2 were confirmed to be actin 
nodules, via identification with immunochemistry of the presence of actin nodule markers; the Arp2/3 complex, 
pan-pTyrosine substrate and WASP (Supplementary Figure S2a,b and data not shown)9. The alterations in actin 
structure was associated with a dynamic change in platelet surface area. It was observed that as the actin struc-
tures rearranged the platelet surface area significantly contracted, but expanded again as the actin stress fibres 
reformed (Fig. 2b,e). Interestingly, the change in actin structures had no effect upon the number of adherent 
platelets (Supplementary Figure S3). In order to identify if the reversal of stress fibre formation is due to a reduc-
tion in actin polymerization induced by PGI2, platelets were allowed to spread on fibrinogen before stimulation 
with PGI2 (10 nM) for 10 minutes. The platelets were then lysed and analysed for the content of filamentous actin. 
Control platelets underwent a 2.0 ± 0.2 fold increase in F-actin polymerisation, which was unaffected by stim-
ulation with PGI2 (2.2 ± 0.3 fold increase), suggesting a targeted modulation of stress fibre formation (Fig. 2f).
To confirm the role for cAMP signalling we used forskolin (Fsk) as a direct activator of adenylyl cyclase. The 
addition of Fsk (1 μM) to adherent platelets led to a significant and sustained reversal of stress fibre formation 
(Supplementary Figure S4a,b), increased actin nodule formation (Supplementary Figure S4a,c), a reduction in 
platelet surface area (Supplementary Figure S4a,e), but did not influence actin polymerisation (Fig. 2f) or platelet 
adhesion (Supplementary Figure S4d). The effects of Fsk were observed at 10 minutes but in contrast to PGI2 were 
maintined for up to 60 minutes (longest time tested) (Supplementary Figure S4).
To determine if the reversal of stress fibres driven by PGI2 was independent of effects on secretion, platelets 
were spread on fibrinogen in the presence of apyrase (2 U/ml) and indomethacin (10 μM) prior to treatment with 
PGI2 (10 nM). The presence of apyrase and indomethacin reduced the number of adherent platelets, but did not 
influence surface area or actin structures of the adherent platelets. Importantly treatment of adherent platelets 
with PGI2 caused a reversal of stress fibre formation, production of actin nodules, and a reduction in surface 
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area. This demonstrates that the effect of PGI2 on the actin cytoskeletal rearrangement is independent of ADP 
and TXA2 bioavailability (Fig. 3). Therefore PGI2 reversed both stress fibre and lamellipodia formation, whilst 
inducing actin nodule formation, independent of platelet secretion.
PGI2 induces cAMP production and activation of the cAMP/PKA pathway in spread plate-
lets. PGI2 induces generation of cAMP and activation of PKA in platelets, although PKA-independent 
signalling is shown in other cell types23, 24. Initially it was confirmed that adherent platelets could synthesise 
cAMP. Treatment of adherent platelets with PGI2 (10 nM) for 2 minutes led to a significant increase in cAMP 
from 152 ± 52 fmol/μg to 1576 ± 293 fmol/μg (p < 0.05) and was consistent with platelets in suspension stimu-
lated with PGI2 for 1 minute25 (Fig. 4a). To confirm that the actin cytoskeletal rearrangements induced by PGI2 
were mediated by PKA the established PKA inhibitors Rp-8cpt-cAMPs (500 μM) and KT5720 (10 μM) were 
Figure 1. Post perfusion of 100 nM PGI2 induces embolisation of performed thrombi on fibrinogen. Whole 
blood, stained with 10 μM DiOC6 was flowed over fibrinogen (300 μg/ml) coated slides for 2 minutes at a shear 
rate of 1000 s−1, to enable the formation of thrombi. After 2 minutes either tyrodes alone or tyrodes containing 
100 nM PGI2 were perfused over the preformed thrombi for 10 minutes at 1000 s−1. (a) Schematic of the 
experimental condition of the flow. (b) Representative images of the thrombi observed under these different 
experimental conditions. Scale bar is 20 μm. The insert shows an enlarged image of their respective images with 
a scale bar of 5 μm. (c) The surface area of the thrombi at 2 minutes of flow and after 10 minutes of perfusion 
with 100 nM PGI2. Thrombi were fixed with 4% paraformaldehyde, before restaining with 10 μM DiOC6 
overnight. Thrombi were then imaged using flourescent microscopy, and analysed using ImageJ to obtain the 
surface area. Analysis completed from n = 3 experiments. p < 0.05.
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employed26, 27. The presence of Rp-8cpt-cAMPs (500 μM) and KT5720 (10 μM) blocked the ability of PGI2 to 
reverse stress fibres, induce actin nodule formation, and reduce platelet spreading (Fig. 4b–e). This data suggests 
PGI2 modulates the actin cytoskeleton in activated spread platelets via a cAMP/PKA dependent mechanism.
Actin nodules represent a pre-stress fibre actin structure9 and our observation that cAMP signalling was asso-
ciated with the reversal of stress fibres led us to examine these nodules in more detail. Firstly, adherent platelets 
were stained for PKARI and RII subunits. Consistent with our previous observations, differential localisation of 
these isoforms was observed with PKARI found at the periphery of the platelet and PKARII distibuted through-
out the platelet (Fig. 5a,b)28. Moreover, PKARII was localized with the actin nodule, while PKARI staining was 
mutually exclusive to the actin cytoskeleton. PKA activity is localised to particular cell compartments in order 
to focus its catalytic activity on to specific substrates. Further analysis using immunofluorescence demonstrated 
the presence of phosphorylated PKA substrates including pRhoAser188 at actin nodules present in spread platelets 
after being treated with PGI2 (Fig. 5c). This suggested that cAMP maybe focussed on the actin nodule associated 
RhoA.
Figure 2. Post treatment of PGI2 induces stress fibre reversal and actin nodule formation in platelets spread 
on fibrinogen in a time dependent manner. Platelets (2 × 107/ml) were spread on 100 μg/ml fibrinogen for 
25 minutes, washed with PBS, and then 10 nM of PGI2 was added, for a further 2–60 minutes as per the 
representative experimental design in part (a) The platelets were then fixed and stained with FITC-phalloidin 
before being imaged via fluorescent microscopy. (b) Representative images of each condition of the experiment. 
(c) The number of spread platelets containing stress fibres was identified in control and PGI2 treated samples. 
(d) The number of spread platelets containing actin nodules was identified in control and PGI2 treated samples. 
(e) The average surface area of the spread platelets was analysed for each timepoint in control and PGI2 treated 
samples. Analysis was performed using Image J. The experiments are an average of n = 5. p < 0.05. Scale-bar 
5 μm. (f) Platelets were spread as above for 25 minutes and then treated for 10 minutes with either 10 nM PGI2 or 
1 μM forskolin. Assessment of the filamentous actin was performed using the F-actin assay. The experiments are 
an average of n = 3.
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PGI2 reverses activation of RhoA in spread platelets. Platelet stress fibre formation requires the acti-
vation of RhoA and its downstream effector ROCK9. Platelets incubated with the ROCK inhibitor Y27632 or the 
RhoA inhibitor Rhosin prior to spreading fail to form stress fibres (Supplementary Figure S5)8. As Fig. 2 had iden-
tified a significant reversal of stress fibre formation in the presence of PGI2, this indicated that PGI2 could reverse 
RhoA activation. To examine this possibility, platelets were spread for 25 minutes, treated with PGI2 (10 nM) 
or Fsk (1 μM) and the phosphorylation of key proteins evaluated. Confirmation of cAMP signalling in adher-
ent platelets was illustrated by the sustained VASP-ser157 phosphorylation in response to PGI2 or Fsk (Fig. 6a,b, 
Supplementary Figure S6 and data not shown). In untreated adherent platelets RhoA was non-phosphorylated. In 
contrast phosphoRhoA-ser188 became apparent after PGI2 (10 nM) and Fsk (1 μM) stimulation, in a PKA depend-
ent manner (Fig. 6a,c, Supplemetary Figure S6 and data not shown). Phosphorylation of RhoA is associated with 
RhoA inactivation, as it binds the GDI subunit, and therefore can no longer cause the activation of ROCK29. 
Analysis of RhoA showed it was activated (GTP-bound) in adherent platelets, but that addition of PGI2 signif-
icantly reduced the active RhoA present within the spread platelets (Fig. 6e,f and Supplementary Figure S6). 
Further to this, and in agreement with a reduction in RhoA activity, PGI2 and Fsk reduced MLC-ser19 phospho-
rylation in spread platelets (Fig. 6a,d and Supplementary Figure S6). These results indicate that PGI2 can inhibit 
the activated RhoA via phosphorylation by a PKA-dependent mechanism.
Discussion
Haemostasis relies on stable platelet adhesion for subsquent thrombus formation. The ability of platelets to 
undergo a rapid remodelling of the actin cytoskeleton is critical in order to withstand shear stress. Indeed an ina-
bility to form lamellipodia or stress fibres upon platelet activation and spreading is linked to thrombus instability 
and embolisation8, 12, 13. However, under physiological conditions these key changes occur in situations where 
platelets are continually exposed to PGI2. Given the key role of RhoGTPases in actin remodelling we examined 
the influence of cAMP signalling on activated platelets, using the platelet spreading and in vitro flow assays. We 
show here that (i) PGI2 can cause the reversal of surface area of platelet aggregates under high shear (ii) PGI2 can 
reverse platelet spreading via dissolution of stress fibres, and the formation of actin nodules in a cAMP/PKA 
dependent mechanism, (iii) PKA localises to the actin nodule, using it as a platform to mediate PKA mediated 
inhibitory phosporylation of RhoA. These data suggest that in addition to its already known roles in causing 
platelet inhibition prior to thrombus formation, cAMP signalling can control the size and stability of existing 
Figure 3. PGI2 reverses stress fibre formation independent of ADP and TXA2. Platelets (2 × 107/ml) were 
spread on 100 μg/ml fibrinogen for 25 minutes with or without apyrase (2 U/ml) and indomethacin (10 μM). The 
platelets were washed, and 10 nM PGI2 added for 10 minutes, in the presence or absence of apyrase (2 U/ml) and 
indomethacin (10 μM). The platelets were then fixed and stained with FITC-phalloidin before being imaged. (a) 
Images are representative of the experimental conditions. (b) The number of platelets containing stress fibres 
or actin nodules in the presence or absence of apyrase (2 U/ml) and indomethacin (10 μM) was identified in 
control and PGI2 treated samples. (c) The total number of platelets adhered, was identified in control and PGI2 
treated samples. (d) The average surface area of the spread platelets was identified in control and PGI2 treated 
samples. The experiments are an average of n = 4. Scale bar is 5 μm. p < 0.05.
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platelet aggregates via modulating the actin cytoskeleton, causing the aggregates to become vulnerable to high 
shear stress.
PGI2 and the PKA signaling pathway have been implicated in actin cytoskeleton modulation in multiple cell 
types15, 20, 21. Although prior incubation of platelets with PGI2 and Fsk leads to inhibition of platelet adhesion, 
spreading and thrombus formation30–33, it is unclear if PGI2 can actively modulate a fully activated platelet. This is 
a critical idea as it demonstrates that PGI2 plays a dual role in the control of thrombus formation, both inhibition 
of platelets prior to activation, and reversal of platelets once they are already active. Both effects could then lead 
to reduction in thrombus formation. The reversal of platelet activation links into recent modelling of thrombus 
formation that suggests a dynamic structure with a core area, within which the platelets are fully activated and 
surrounded by a pheripheral area in which the activatory signals are much weaker2. The balance between the 
activatory and inhibitory signals acting on the platelets likely determines their activatory status. Therefore we 
set out to explore how PGI2 affected preexisting platelet aggregates. Using an in vitro flow assay we show for the 
first time that post perfusion of thrombi on fibrinogen with PGI2 caused a significant reduction in surface area. 
The ability of the platelet to withstand high shear is driven, at least in part, by the formation of remodelled actin 
structures within the platelet and we focussed our investigation on these processes. Platelet spreading was associ-
ated with progressive changes in actin structures including filopodia, actin nodules, lamellipodia and ultimately 
stress fibres. Addition of PGI2 to spread platelets induced cytoskeletal remodelling associated with stress fibre 
Figure 4. Reversal of platelet stress fibre formation and induction of actin nodule formation is dependent on 
PKA activation. Platelets (2 × 107/ml) were spread on 100 μg/ml fibrinogen for 25 minutes in the presence or 
absence of PKA inhibitors; 500 μM RP-8-CPT-cAMP (RP) and 10 μM KT5720 (KT), before being washed with 
PBS. The platelets were then treated with tyrodes containing 10 nM PGI2 or 1 μM forskolin with or without PKA 
inhibitors 500 μM RP-8-CPT-cAMP and 10 μM KT5720, for a further 10 minutes. The platelets were then fixed, 
stained with FITC-phalloidin and imaged. (a) The levels of cAMP were assessed in basal suspended platelets, 
control and 10 nM PGI2 treated spread platelets. (b) Representative images of spread platelets under different 
experimental conditions. (c) The number of spread platelets containing stress fibres were identified for each 
condition in control and treated samples. (d) The number of spread platelets containing actin nodules were 
identified for each condition in control and treated samples. (e) The average surface area of the spread platelets 
was analysed for each condition in control and treated samples using Image J. The experiments are an average of 
n = 3. p < 0.05. Scale bar is 5 μm.
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dissolution consistent with previous observations in other cell types22, 34. The effects of PGI2 were mimicked by 
forskolin, but blocked by PKA inhibitors, indicating a central role for the cAMP-PKA signalling cascade.
To examine the mechanism that underpinned stress fibre disassembly and actin nodule formation we used a 
pharmacolgical approach. Incubation of platelets with RhoA and ROCK inhibitors, led to adherent platelets rich 
Figure 5. Actin nodules contain PKA signalling proteins. Platelets (2 × 107/ml) were spread on 100 μg/ml 
fibrinogen for 25 minutes before being washed with PBS. The platelets were then treated with tyrodes with 
or without 10 nM PGI2 for a further 10 minutes. The platelets were then fixed, lysed and stained for either (a) 
PKA RI (1:100), (b) PKA RII (1:100) or (c) pRhoA (1:1000); and co-stained with actin (FITC-Phalloidin) for 
60 minutes, before mounting and imaging the slides. Images are representative of at least 3 experiments. Scale 
bar is 5 μm.
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in actin nodules and an absence of stress fibres as reported previously8. Since the addition of PGI2 led to a loss 
of stress fibres, we speculated that PGI2 may target RhoA signalling in adherent platelets. Consistent with our 
previous studies in suspended platelets we found that PGI2 increased the inhibitory phosphorylation of RhoA at 
ser188 and reduced the GTP-loading of RhoA. Here we have extended our original findings to show that cAMP 
signalling can switch off activated RhoA in addition to blocking its activation. The inhibition of RhoA/ROCK 
signalling led to dephosphorylation of MLC, which likely occurs through the ability of cAMP signalling to induce 
disinhibition of MLCP. Moreover we show that the inhibitory phosphorylation of RhoA identified by immunob-
lotting is primarily located at the actin nodule. The actin nodule was identified as an F-actin rich structure that 
was formed in spreading platelets prior to lamellipodia formation9 that required both the Arp2/3 complex and 
WASp, and are sites of tyrosine kinase signalling activity35. Given that RhoA phosphorylation is mediated by PKA 
we also examined the presence of the kinase. cAMP signalling events are highly regulated and involve the selec-
tive coupling of cAMP signalling complexes to specific substrates or regions within the cell (Reviewed in ref. 36). 
Our data suggest that the actin nodule may act as such a signalling platform allowing localisation of PKAII, but 
not PKAI, and several phosphorylated PKA substrates. These data suggest that PKAII specifically targets RhoA 
and that this inhibitory phosphorylation prevents sustained stress fibre formation allowing reversion to actin 
Figure 6. PGI2 induces a PKA signalling response in spread platelets. Platelets (2 × 108/ml) were spread on 
100 μg/ml fibrinogen for 25 minutes in the presence or absence of PKA inhibitors 100 μM RP-8CPT-cAMP 
(RP) and 2 μM KT5720 (KT), before being washed with PBS. (a) The platelets were then treated with tyrodes 
containing 10 nM PGI2 with or without PKA inhibitors (100 μM RP-8CPT-cAMP and 2 μM KT5720), or 
1 μM forskolin, or Y27632 (10 μM), for a further 10 minutes. The samples were then lysed with laemelli buffer 
before being western blotted for pVASPser159, pMLCser19, pRhoAser188, and GAPDH. Cropped gel Images are 
representative of at least three experiments (full length gels are illustrated in Supplementary Figure S6). (b–d) 
Densitometry for the western blots; pVASPser159, pMLCser19 and pRhoAser188 using GAPDH as the loading 
control. The ratios were standardised to the control. (e) Spreading the platelets as above, they were treated with 
tyrodes containing 10 nM PGI2 with or without PKA inhibitors 100 μM RP-8CPT-cAMP and 2 μM KT5720 
for a further 10 minutes. The samples were then lysed, before the addition of RhoA GTP beads. Samples were 
then western blotted for active RhoA and total RhoA. Cropped gel Images are representative of at least three 
experiments (full length gels are illustrated in Supplementary Figure S6). (f) Images of RhoA pull down were 
analysed for densitometry (full length gels are illustrated in Supplementary Figure S6). Analysis is an average of 
at least n = 3 experiments. p < 0.05.
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nodules. This is in addition to the previous identification of Rac puts forward the interesting hypothesis that the 
nodule is under the control of both Rac and RhoA, and that the interplay between the level of activation of both 
is critical to actin nodule formation and dissolution.
This reversal of stress fibres on fibrinogen links with the thrombus defect as stress fibre formation is critical to 
withstand high shear8. The physiogical importance of our observations relates to the environment of the growing 
thrombus. The data indicates that the reversal of platelet aggregate formation by PGI2 is due to its effect on the 
upper layers of the thrombus, which are linked by the exposure of fibrinogen. Furthermore, thrombin and TXA2 
generated at the sites of thrombus formation further activate platelets but also stimulate the biosynthesis of PGI2 
by the blood vessel wall4. It is possible that in addition to preventing excessive platelet activation the release of 
PGI2 in areas of vascular damage could modulate thrombus formation through regulating thrombus stability. 
Indeed the model proposed by Welsh et al.3 of graded platelet activation through the thrombus could be explained 
at least in part by our observations. Thrombi have been postulated to be made up of a core area, within which the 
platelets are fully activated as they have a multitude of activatory signals. This core area is surrounded by a periph-
eral area where the activatory signals are much weaker, and platelets are known to bind transiently to the growing 
thrombi. Exposure of these peripheral platelets to PGI2 may facilitate their embolisation and contribute to the 
control of thrombosis. It would be highly interesting to extend this work through understanding how this effect 
of platelet reversal interplays with the activation of the coagulation system, and the formation of fibrin, through 
the action of thrombin. Thrombin activation of platelets has previously been identified to be inhibited by PGI2, 
so can PGI2 reverse its activation? How would this reversal affect the formation of fibrin? Indeed, is PGI2 reversal 
of platelet activation required to prevent excessive fibrinogen exposure, and therefore excessive fibrin formation. 
This potentially ties in with the altered fibrin formation associated with thrombi from patients with pulmonary 
arterial hypertension. Within this condition there is reduced PGI2 production, and thrombi with altered fibrin 
formation, that is resistant to lysis37. Therefore is the reduction in PGI2 inducing excessive fibrin formation due to 
an inability to reverse platelet activation? Furthermore given the importance of PGI2 in both the initial inhibition, 
and also the reversal of thrombus formation, this data strengthens the case for the development of anti-platelet 
drug therapies that target cAMP elevation for the control of thrombus formation.
However, importantly this report identifies PGI2 mediated reversal of platelet activation. This reversal of acti-
vation, through the control of activity of RhoA, could have a signficant effect upon the capability of the platelet 
to work effectively in a high shear environment. This report therefore demonstrates a novel mechanism by which 
PGI2 regulates platelet activation through continous modulation of RhoA and stress fibre formation.
Material and Methods
Materials. PGI2 (Cayman Chemical, Michigan, USA), Forskolin (Sigma-Aldrich, UK), Fibrinogen (Enzyme 
Research, Swansea, UK), Y-27632 (Abcam, Cambridge, UK), Rp-8CPT-cAMP (Biolog, Bremen, Germany), 
KT5720 (Abcam, Cambridge, UK), pRhoAser188 (Santa-Cruz Biotechnology, Heidelberg, Germany), pMLCser19 
and pVASPser157 (New England Biolabs, Hitchin, UK), GAPDH and Arp2/3 (Millipore, Watford, Hertfordshire, 
UK), PKA RI (Cell Signalling Technology, Leiden, Netherlands), PKARII (BD Biosciences, Oxford, UK), pPKA 
substrate (Cell Signalling Technology, Leiden, Netherlands), WASP (Santa-Cruz Biotechnology, Heidelberg, 
Germany), pTyrosine (Cytoskeleton, Denver, UK), RhoA pulldown kit (Cytoskeleton, Denver, UK), cAMP assay 
and ProLong Diamond Antifade Mountant (GE healthcare, Little Chalfont, Buckinghamshire, UK), Flourescent 
secondary anti-mouse 800 and anti-rabbit 680 antibodies (LI-COR Biotechnology, Cambridge, UK) All other 
chemicals were from Sigma Ltd (Poole, UK) unless otherwise stated.
Platelet preparation. Whole blood was mixed with acid-citrate dextrose (ACD; 5:1) (114 mM glucose, 
30 mM Tris-Na Citrate, 72.6 mM NaCl and 3.0 mM citric acid pH 6.4) and platelets were isolated using low pH as 
previously described18. Platelets were allowed to rest for 30 minutes prior to experimentation. Written informed 
consent was acquired for the donation of blood. The work was conducted in accordance with the relevant guide-
lines and regulations and was completed under the ethical permission granted by the Hull York Medical School 
ethical committee, for “The study of platelet activation, signalling and metabolism”.
Platelet Spreading. Coverslips were incubated with fibrinogen (100 μg/ml) overnight at 4 °C, washed with 
PBS and blocked with denatured fatty acid free BSA (5 mg/ml) for 1 hour at room temperature. Platelets (2 × 107/
ml) were adhered to immobilised proteins for 25 minutes at 37 °C in the presence or absence of Apyrase (2 U/
ml), Indomethacin (10 μM), or Rp-8-CPT-cAMP (500 μM) and KT5720 (10 μM). After 25 minutes the coverslips 
were washed twice with PBS to remove nonadhered platelets and then treated with PGI2 (1-1000 nM) or forsko-
lin (0.1–100 μM) in the presence or absence of Apyrase (2 U/ml), Indomethacin (10 μM), or Rp-8-CPT-cAMP 
(500 μM) and KT5720 (10 μM). At the required timepoint the platelets were fixed with 4% paraformaldehyde for 
10 minutes, lysed with 0.1% Triton X-100, stained with FITC-phalloidin and if required the relevant primary anti-
body (PKARI, and PKARII (1:100), pRhoAser188, Arp2/3, and 4G10 (1:1000)), followed by the secondary antibody 
(1:200), mounted and visualized using a Zeiss Axio Observer (Zeiss, Cambridge, UK) with a x63 oil immersion 
objective (1.4 NA) and Zen Pro software (Carl Zeiss, Cambridge, UK). Images of spread platelets were analysed 
using ImageJ software (NIH, Bethesda, USA) to identify the surface area, the platelets containing either actin 
nodules or stress fibres, and platelet adhesion. In some cases platelets (2 × 107/ml) were preincubated with PGI2 
(1–1000 nM) or Forskolin (0.1–100 μM), for 2 minutes prior to adhesion for 45 minutes.
In vitro Flow Assay. Flow studies were performed with multichannel biochips (Cellix, Dublin Ireland). 
Biochips were coated with 300  μg/ml fibrinogen overnight at 4 °C and blocked with denatured BSA (5 mg/ml) for 
1 hour. Whole blood was stained with DIOC6 (10 μM) and flowed through the biochips for 2 minutes at a shear 
rate of 1000 s−1 at 37 °C. Biochips then underwent a post-flow with Tyrode’s buffer supplemented with or without 
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PGI2 (100 nM; 1000 s−1 at 37 °C) for 10 minutes, before fixation with 4% paraformaldehyde, staining overnight 
with DiOC6 (10 μM) and imaging using a Apotome.2 confocal unit on a Zeiss Axio Observer (Zeiss, Cambridge, 
UK) with a x63 oil immersion objective (1.4 NA) and Zen Pro software (Carl Zeiss, Cambridge, UK). Analysis of 
the surface area coverage of each condition was performed using ImageJ software (NIH, Bethesda, USA).
Immunoblotting. Six well plates were coated with fibrinogen as per platelet spreading. Platelets (2 × 108/
ml) were adhered for 25 minutes before removal of non-adherent platelets. Adherent platelets were then treated 
with PGI2 (10 nM), FSK (1 μM), or Y27632 (10 μM) in the presence or absence of Rp-8CPT-cAMP (500 μM) and 
KT5720 (10 μM). Platelets were lysed with Laemelli buffer and the lysates were separated by SDS-PAGE, trans-
ferred and immunoblotted with the required antibodies (pVASPser157 (1:1000), pRhoAser188 (1:1000), pMLCser19 
(1:1000), or GAPDH (1:6000)). The blots were imaged by Odyssey CLx Infrared Imaging system (LI-COR 
Biotechnology, Cambridge, UK), and densitometry was analysed by Image Studio ver.5.2 (LI-COR Biotechnology, 
Cambridge, UK).
F-actin Analysis. Six well plates were coated with fibrinogen as per platelet spreading. Platelets (2 × 108/ml) 
platelets were adhered for 25 minutes before being washed with PBS. The platelets were then treated with Tyrode’s 
buffer, PGI2 (10 nM) or FSK (1 μM) for 10 minutes. The samples were processed as previously described38. 
Aliquots of unstimulated platelets (1 × 108/ml to 8 × 108/ml) were used to calculate both the protein concentra-
tion and F-actin concentration at these platelet numbers as an unstimulated control.
Measurement of cAMP and RhoA Pull-down assay. Six well plates were coated with fibrinogen as per 
platelet spreading. Platelets (2 × 108/ml) were spread for 25 minutes before washing, and treatment with Tyrodes 
buffer or PGI2 (10 nM) for 2 minutes. Platelets were lysed and cAMP concentrations measured using a commeri-
cal available assay kit18. For the RhoA pull down platelets the samples were prepared as above, but then lysed and 
lysates incubated for 90 minutes at 4 °C with Rhotekin-RBD-beads. Bead pellets were washed once and Laemmeli 
buffer was added prior to immunoblotting as previously published39.
Statistical analysis. Results are shown as mean ± standard error of mean (SEM). Data was arcsin trans-
formed as appropriate and then subject to statistical analysis. Statistical analysis was performed by using one-way 
ANOVA with a P value of < 0.05.
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